Effectiveness of vero cell inactivated vaccine against severe acute respiratory infections (SARI) in Sibu, Malaysia: A retrospective test-negative design

References

• World Health Organization. WHO COVID-19 Dashboard. Geneva: World Health Organization; 2020.
   Google Scholar
• Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, Khrisna CV, Sari RM, Setyaningsih L, Surachman F, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine. 2021;39:(44):6520–7. doi:10.1016/j.vaccine.2021.09.052.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:(10296)213–22. doi:10.1016/S0140-6736(21)01429-X.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Geneva: 2022 Mar 15 [accessed 2022 May 17]. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1.
   Google Scholar
• Hashim JH, Adman MA, Hashim Z, Mohd Radi MF, Kwan SC. COVID-19 epidemic in Malaysia: epidemic progression, challenges, and response. Front Public Health. 2021;9:560592. doi:10.3389/fpubh.2021.560592.
   PubMed Web of Science ®Google Scholar
• Sam IC, Chong YM, Abdullah A, JYL F, Hasan MS, Jamaluddin FH, Kamarulzaman A, Lim KK, Mohd nor MA, Pang YK, et al. Changing predominant SARS-CoV-2 lineages drives successive COVID-19 waves in Malaysia, February 2020 to March 2021. J Med Virol. 2021;94(3):1146–53. doi:10.1002/jmv.27441.
   PubMed Web of Science ®Google Scholar
• Perera D. Sarawak COVID-19 genomic surveillance statement. 2021.
   Google Scholar
• Muhamad Khair NK, Lee KE, Mokhtar M. Community-based monitoring in the new normal: a strategy for tackling the COVID-19 pandemic in Malaysia. Int J Environ Res Public Health. 2021;18(13):6712. doi:10.3390/ijerph18136712.
   PubMed Web of Science ®Google Scholar
• Jayasundara P, Peariasamy KM, Law KB, Abd Rahim KNK, Lee SW, Ghazali IMM, Abayawardana M, Le L-V, Khalaf RKS, Razali K, et al. Sustaining effective COVID-19 control in Malaysia through large-scale vaccination. Epidemics. 2021;37:100517. doi:10.1016/j.epidem.2021.100517.
   PubMed Web of Science ®Google Scholar
• Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA, Lanata CF, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization. Vaccine. 2021;39(30):4013–24. doi:10.1016/j.vaccine.2021.05.099.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO surveillance case definitions for ILI and SARI. Geneva: WHO [Internet]; 2018.
   Google Scholar
• World Health Organization. WHO COVID-19 Case definition: Updated in Public health surveillance for COVID-19. Geneva: World Health Organization; 2022 Jul 2 [accessed 2021 Jan 20]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022.1.
   Google Scholar
• World Health Organization. Evaluation of COVID-19 vaccine effectiveness: interim guidance. Geneva: World Health Organization; 2021.
   Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat - Simul Comput. 2009;38(6):1228–34. doi:10.1080/03610910902859574.
   Web of Science ®Google Scholar
• Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–84. doi:10.1056/NEJMoa2107715.
   PubMed Web of Science ®Google Scholar
• McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, Wu P, Leung G, Cowling BJ. Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong. medRxiv 2022:2022.03.22.22272769. doi:10.2139/ssrn.4064649.
   Google Scholar
• Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, Guan W-J, Gan L, Li Y-L, Liu W-H, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. Emerg Microbes Infect. 2021;10:(1):1751–59. doi:10.1080/22221751.2021.1969291.
   PubMed Web of Science ®Google Scholar
• Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, Lye DC, Lee VJ, Tan KB. Comparative effectiveness of mRNA and inactivated whole virus vaccines against COVID-19 infection and severe disease in Singapore. Clin Infect Dis. 2022;75(8):1442–45. doi:10.1093/cid/ciac288.
   PubMed Web of Science ®Google Scholar
• Suah JL, Husin M, Tok PSK, Tng BH, Thevananthan T, Low EV, Appannan MR, Muhamad Zin F, Mohd Zin S, Yahaya H, et al. Waning COVID-19 vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study. Int J Infect Dis. 2022;119:69–76. doi:10.1016/j.ijid.2022.03.028.
   PubMed Web of Science ®Google Scholar
• Fan VS, Dominitz JA, Eastment MC, Locke ER, Green P, Berry K, O’Hare AM, Shah JA, Crothers K, Ioannou GN. Risk factors for testing positive for severe acute respiratory syndrome coronavirus 2 in a National United States healthcare system. Clin Infect Dis. 2021;73(9):e3085–94. doi:10.1093/cid/ciaa1624.
   PubMedGoogle Scholar
• Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Bmj. 2020;369:m1966. doi:10.1136/bmj.m1966.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, de Lusignan S, Andrews N, Byford R, Dabrera G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford royal college of general practitioners research and surveillance centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20(9):1034–42. doi:10.1016/S1473-3099(20)30371-6.
   PubMed Web of Science ®Google Scholar
• Prinelli F, Bianchi F, Drago G, Ruggieri S, Sojic A, Jesuthasan N, Molinaro S, Bastiani L, Maggi S, Noale M, et al. Association between smoking and SARS-CoV-2 infection: cross-sectional study of the EPICOVID19 internet-based survey. JMIR Public Health Surveill. 2021;7(4):e27091. doi:10.2196/27091.
   PubMedGoogle Scholar
• Ismail N, Hassan N, Abd Hamid MHN, Yusoff UN, Khamal NR, Omar MA, Wong XC, Pathmanathan MD, Mohd Zin S, Muhammad Zin F, et al. Association of smoking and severity of COVID-19 infection among 5,889 patients in Malaysia: a multi-center observational study. Int J Infect Dis. 2022;116:189–96. doi:10.1016/j.ijid.2022.01.011.
   PubMed Web of Science ®Google Scholar
• Sim BLH, Chidambaram SK, Wong XC, Pathmanathan MD, Peariasamy KM, Hor CP, Chua HJ, Goh PP. Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study. Lancet Reg Health West Pac. 2020;4:100055. doi:10.1016/j.lanwpc.2020.100055.
   PubMedGoogle Scholar